Erik Berntorp
1 – 50 of 329
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Health-related quality of life and physical activity in Nordic patients with moderate haemophilia A and B (the MoHem study)
(
- Contribution to journal › Article
- 2023
-
Mark
Impact of timing of prophylaxis commencement, F8 genotype and age on factor consumption and health-related quality of life in patients with severe haemophilia A
(
- Contribution to journal › Article
-
Mark
No difference in quality of life between persons with severe haemophilia A and B
(
- Contribution to journal › Article
-
Mark
Immune tolerance induction in development
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Area under the curve : Comparing the value of factor VIII replacement therapies in haemophilia A
(
- Contribution to journal › Article
-
Mark
A need to increase von Willebrand disease awareness : vwdtest.com – A global initiative to help address this gap
(
- Contribution to journal › Scientific review
-
Mark
Clinical, economic, and health-related quality of life burden associated with von Willebrand disease in adults and children : Systematic and targeted literature reviews
(
- Contribution to journal › Scientific review
-
Mark
Applicability of the European Society of Cardiology Guidelines on the management of acute coronary syndromes to older people with haemophilia A – A modified Delphi consensus by the ADVANCE Working Group
(
- Contribution to journal › Scientific review
-
Mark
Prophylaxis use of clotting factor replacement products in people with non-severe haemophilia : A review of the literature
(
- Contribution to journal › Scientific review
- 2022
-
Mark
Clinical outcome and adherence rate in Scandinavian patients with intermediate-intensity prophylaxis before and after the switch of standard half-life FVIII products to BAY 81–8973
(
- Contribution to journal › Article
-
Mark
Alternative payment models for durable and potentially curative therapies : The case of gene therapy for haemophilia A
(
- Contribution to journal › Article
-
Mark
Sixth Åland Island Conference on von Willebrand disease
(
- Contribution to journal › Article
-
Mark
Factor IX antibodies and tolerance in hemophilia B in the Nordic countries - The impact of F9 variants and complications
(
- Contribution to journal › Article
-
Mark
Quality of life in a large multinational haemophilia B cohort (The B-Natural study) – Unmet needs remain
(
- Contribution to journal › Article
- 2021
-
Mark
Translating the success of prophylaxis in haemophilia to von Willebrand disease
(
- Contribution to journal › Scientific review
-
Mark
Haemophilia early arthropathy detection with ultrasound and haemophilia joint health score in the moderate haemophilia (MoHem) study
(
- Contribution to journal › Article
-
Mark
In response to WFH guidelines for the management of haemophilia, 3rd edition : Is there a difference between extended-half-life FVIII products or not?
(
- Contribution to journal › Letter
-
Mark
Bleeding phenotype of patients with moderate haemophilia A and B assessed by thromboelastometry and thrombin generation
(
- Contribution to journal › Article
-
Mark
Optimising prophylaxis in haemophilia A : The ups and downs of treatment
(
- Contribution to journal › Scientific review
-
Mark
The B-Natural study—The outcome of immune tolerance induction therapy in patients with severe haemophilia B
(
- Contribution to journal › Article
-
Mark
Haemophilia
(
- Contribution to journal › Scientific review
-
Mark
A comparison of MyPKFiT and WAPPS-Hemo as dosing tools for optimizing prophylaxis in patients with severe haemophilia A treated with Octocog alfa
(
- Contribution to journal › Article
-
Mark
Treatment outcomes in persons with severe haemophilia B in the Nordic region : The B-NORD study
(
- Contribution to journal › Article
-
Mark
Natural history study of factor IX deficiency with focus on treatment and complications (B-Natural)
(
- Contribution to journal › Article
- 2020
-
Mark
Achieving the unimaginable : Health equity in haemophilia
(
- Contribution to journal › Scientific review
-
Mark
Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach
(
- Contribution to journal › Article
-
Mark
Joint health and treatment modalities in Nordic patients with moderate haemophilia A and B – The MoHem study
(
- Contribution to journal › Article
-
Mark
Direct comparison of two extended half-life PEGylated recombinant FVIII products : a randomized, crossover pharmacokinetic study in patients with severe hemophilia A
(
- Contribution to journal › Article
-
Mark
Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease : Results from 3WINTERS-IPS, an international and collaborative cross-sectional study
(
- Contribution to journal › Article
-
Mark
Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis
(
- Contribution to journal › Article
- 2019
-
Mark
Evaluation of a standardized protocol for thrombin generation using the calibrated automated thrombogram : A Nordic study
(
- Contribution to journal › Article
-
Mark
ROTEM and vitro reversal of warfarin with APCC
(
- Contribution to journal › Article
-
Mark
Factor VIII : Long-established role in haemophilia A and emerging evidence beyond haemostasis
(
- Contribution to journal › Scientific review
-
Mark
Sports participation and physical activity in adult Dutch and Swedish patients with severe haemophilia : A comparison between intermediate- and high-dose prophylaxis
(
- Contribution to journal › Article
-
Mark
Cardiovascular disease-related hospitalization and mortality among persons with von Willebrand disease : A nationwide register study in Sweden
(
- Contribution to journal › Article
-
Mark
Coagulation factor VIII is vital for increasing global coagulation after physical exercise
(
- Contribution to journal › Article
-
Mark
Moderate haemophilia in focus
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Hypertension and cardiovascular diseases in Swedish persons with haemophilia — A longitudinal registry study
(
- Contribution to journal › Article
-
Mark
Direct comparison of two extended-half-life recombinant FVIII products : a randomized, crossover pharmacokinetic study in patients with severe hemophilia A
(
- Contribution to journal › Article
-
Mark
A personalized approach to the management of VWD
(
- Contribution to journal › Article
-
Mark
Joint comorbidities among Swedish carriers of haemophilia : A register-based cohort study over 22 years
(
- Contribution to journal › Article
-
Mark
Evolution of replacement therapy for von Willebrand disease : From plasma fraction to recombinant von Willebrand factor
(
- Contribution to journal › Scientific review
-
Mark
Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders : An EHA Consensus Report
(
- Contribution to journal › Article
- 2018
-
Mark
Fifth Åland Island conference on von Willebrand disease
(
- Contribution to journal › Article
-
Mark
Defining extended half-life rFVIII-A critical review of the evidence
(
- Contribution to journal › Article
-
Mark
The elevated prevalence of risk factors for chronic liver disease among ageing people with hemophilia and implications for treatment
(
- Contribution to journal › Article
-
Mark
Immune tolerance induction : What have we learned over time?
(
- Contribution to journal › Scientific review
-
Mark
Bleeding-related hospitalization in patients with von Willebrand disease and the impact of prophylaxis : Results from national registers in Sweden compared with normal controls and participants in the von Willebrand Disease Prophylaxis Network
(
- Contribution to journal › Article
-
Mark
Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII
(
- Contribution to journal › Article
-
Mark
Replacement therapy during surgery in von Willebrand disease needs personalization
(
- Contribution to journal › Debate/Note/Editorial